CEACAM6

Cancer Immunotherapy Stocks - Tapping into Immune Systems for Next Generation Treatments

Retrieved on: 
Thursday, February 15, 2024
Neoplasm, Doctor of Philosophy, Immunotherapy, SCCA, News, Pharmaceutics, Destiny, PR, Optimism, Poster, Anal cancer, Pancreatic cancer, Anal, CEACAM6, Brigham and Women's Hospital, Bristol Myers Squibb, Therapy, Immune system, Pelareorep, International, Breast cancer, Fast track (FDA), Serology, AIO, Hospital, Hope, Principal investigator, HGG, Conference, Safety, Biomarker, Tumor microenvironment, Patent, Clinical trial, Survival, Harvard Medical School, Acute lymphoblastic leukemia, Injection, MSI, MD, BioNTech, FDA, TSX, Cancer, Entrepreneurship, Prevalence, American depositary receipt, Anal canal, Patient, Cone Health Women's Hospital, ONC, Pharmaceutical industry

According to the American Association for Cancer Research "Cancer immunotherapeutics work by unleashing the power of a patient's immune system to fight cancer and, over the last decade, have emerged as one of the most exciting new approaches to cancer treatment."

Key Points: 
  • According to the American Association for Cancer Research "Cancer immunotherapeutics work by unleashing the power of a patient's immune system to fight cancer and, over the last decade, have emerged as one of the most exciting new approaches to cancer treatment."
  • Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) is developing pelareorep, a unique immunotherapy with the power to awaken the immune system and unlock its antitumor potential.
  • It is committed to delivering the power of T cells and to unlocking new avenues for patients in their fight against cancer.
  • Bristol-Myers Squibb and Fate Therapeutics are some of the other key patent filers in cancer immunotherapy."

Oncolytics Biotech® Presents Updated Clinical Data at SITC Annual Meeting Showing a 69% Objective Response Rate and Confirmed Complete Response in GOBLET Study's Pancreatic Cancer Cohort

Retrieved on: 
Thursday, November 10, 2022
Lymphatic system, Forward-looking statement, 2012 Vuelta a España, Stage 1 to Stage 11, ONC, DKG, Convention center, Pancreatic cancer, MPH, University of Ulm, PDAC, Annual general meeting, Interim, Immunotherapy, Research, Neoplasm, Travel, Boston Convention and Exhibition Center, KOL, COVID-19, Beth Israel Deaconess Medical Center, Goblet cell, Cancer, CEACAM6, PD-L1, NASDAQ, Pelareorep, Patient, Safety, Securities Exchange Act of 1934, Time, Oncology, Biomarker, Company, Science, AB, Clinical trial, Stage 2, Poster, Society for Immunotherapy of Cancer, Biotechnology, TSX, DOI, CBR, LINK, ORR, Phenotype, Regulation, SITC, AIO, Pharmaceutical industry, Risk management, Medical imaging, Oncolytics Biotech

SAN DIEGO, Calif and CALGARY, AB, Nov. 10, 2022 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced updated results from the phase 1/2 GOBLET study's first-line advanced/metastatic pancreatic ductal adenocarcinoma (PDAC) cohort. Patients in this cohort are treated with the combination of pelareorep, Roche's anti-PD-L1 checkpoint inhibitor atezolizumab, and the chemotherapeutic agents gemcitabine and nab-paclitaxel. The updated data are featured in a poster presentation at the ongoing Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, which is taking place both virtually and in-person at the Boston Convention and Exhibition Center in Boston, MA.  

Key Points: 
  • (NASDAQ: ONCY) (TSX: ONC) today announced updated results from the phase 1/2 GOBLET study's first-line advanced/metastatic pancreatic ductal adenocarcinoma (PDAC) cohort.
  • Patients in this cohort are treated with the combination of pelareorep, Roche's anti-PD-L1 checkpoint inhibitor atezolizumab, and the chemotherapeutic agents gemcitabine and nab-paclitaxel.
  • Objective response rate (ORR) and clinical benefit rate (CBR) in GOBLET's PDAC cohort (n=13) were 69% and 85%, respectively, asof the SITC poster's data cutoff date (October 12, 2022).
  • We were particularly excited to see a partial response deepen into a confirmed complete response as of the latest data cut, since this further indicates potentially durable anti-cancer effects from the combination therapy."

Oncolytics Biotech® Presents Updated Clinical Data at SITC Annual Meeting Showing a 69% Objective Response Rate and Confirmed Complete Response in GOBLET Study's Pancreatic Cancer Cohort

Retrieved on: 
Thursday, November 10, 2022
Lymphatic system, Forward-looking statement, 2012 Vuelta a España, Stage 1 to Stage 11, ONC, DKG, Convention center, Pancreatic cancer, MPH, University of Ulm, PDAC, Annual general meeting, Interim, Immunotherapy, Research, Neoplasm, Travel, Boston Convention and Exhibition Center, KOL, COVID-19, Beth Israel Deaconess Medical Center, Goblet cell, Cancer, CEACAM6, PD-L1, NASDAQ, Pelareorep, Patient, Safety, Securities Exchange Act of 1934, Time, Oncology, Biomarker, Company, Science, AB, Clinical trial, Stage 2, Poster, Society for Immunotherapy of Cancer, Biotechnology, TSX, DOI, CBR, LINK, ORR, Phenotype, Regulation, SITC, AIO, Pharmaceutical industry, Risk management, Medical imaging, Oncolytics Biotech

SAN DIEGO, Calif and CALGARY, AB, Nov. 10, 2022 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced updated results from the phase 1/2 GOBLET study's first-line advanced/metastatic pancreatic ductal adenocarcinoma (PDAC) cohort. Patients in this cohort are treated with the combination of pelareorep, Roche's anti-PD-L1 checkpoint inhibitor atezolizumab, and the chemotherapeutic agents gemcitabine and nab-paclitaxel. The updated data are featured in a poster presentation at the ongoing Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, which is taking place both virtually and in-person at the Boston Convention and Exhibition Center in Boston, MA.  

Key Points: 
  • (NASDAQ: ONCY) (TSX: ONC) today announced updated results from the phase 1/2 GOBLET study's first-line advanced/metastatic pancreatic ductal adenocarcinoma (PDAC) cohort.
  • Patients in this cohort are treated with the combination of pelareorep, Roche's anti-PD-L1 checkpoint inhibitor atezolizumab, and the chemotherapeutic agents gemcitabine and nab-paclitaxel.
  • Objective response rate (ORR) and clinical benefit rate (CBR) in GOBLET's PDAC cohort (n=13) were 69% and 85%, respectively, asof the SITC poster's data cutoff date (October 12, 2022).
  • We were particularly excited to see a partial response deepen into a confirmed complete response as of the latest data cut, since this further indicates potentially durable anti-cancer effects from the combination therapy."

Oncolytics Biotech® Reports Interim Results from Phase 1/2 GOBLET Study Showing a 70% Objective Response Rate in Pancreatic Cancer at the SITC Annual Meeting

Retrieved on: 
Monday, November 7, 2022
Lymphatic system, Science, International, Boston Convention and Exhibition Center, DKG, Pelareorep, Stage 2, AIO, Securities Exchange Act of 1934, Interim, Travel, Clinical trial, DOI, SITC, Convention center, Company, Neoplasm, Journal, Immunotherapy, TSX, Phenotype, Cancer, Forward-looking statement, AB, Society, Patient, ORR, Investor relations, Progression-free survival, Research, CEACAM6, KOL, PDAC, LINK, Biotechnology, Breast, COVID-19, Annual general meeting, Pancreatic cancer, 2012 Vuelta a España, Stage 1 to Stage 11, Survival, Society for Immunotherapy of Cancer, MSI, Anal cancer, Time, JITC, Goblet cell, Safety, Biomarker, ONC, Poster, Standard of care, Regulation, NASDAQ, Roche, Oncology, Birth control, Pharmaceutical industry, Medical imaging, Oncolytics Biotech

(NASDAQ: ONCY) (TSX: ONC) today reported interim results from the phase 1/2 GOBLET study's first-line advanced/metastatic pancreatic ductal adenocarcinoma (PDAC) cohort in an abstract published as part of the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting.

Key Points: 
  • (NASDAQ: ONCY) (TSX: ONC) today reported interim results from the phase 1/2 GOBLET study's first-line advanced/metastatic pancreatic ductal adenocarcinoma (PDAC) cohort in an abstract published as part of the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting.
  • "Further, PD-(L)1 inhibitors only benefit fewer than one percent of pancreatic cancer patients classified as MSI-high.
  • Dr. Matt Coffey, President and Chief Executive Officer of Oncolytics Biotech Inc., commented, "GOBLET's interim results represent a crucial clinical milestone, providing robust proof-of-concept in a difficult-to-treat indication.
  • Alongside this potential PDAC opportunity, Oncolytics continues to advance pelareorep towards a registration study in metastatic breast cancer.

Oncolytics Biotech® Reports Interim Results from Phase 1/2 GOBLET Study Showing a 70% Objective Response Rate in Pancreatic Cancer at the SITC Annual Meeting

Retrieved on: 
Monday, November 7, 2022
Lymphatic system, Science, International, Boston Convention and Exhibition Center, DKG, Pelareorep, Stage 2, AIO, Securities Exchange Act of 1934, Interim, Travel, Clinical trial, DOI, SITC, Convention center, Company, Neoplasm, Journal, Immunotherapy, TSX, Phenotype, Cancer, Forward-looking statement, AB, Society, Patient, ORR, Investor relations, Progression-free survival, Research, CEACAM6, KOL, PDAC, LINK, Biotechnology, Breast, COVID-19, Annual general meeting, Pancreatic cancer, 2012 Vuelta a España, Stage 1 to Stage 11, Survival, Society for Immunotherapy of Cancer, MSI, Anal cancer, Time, JITC, Goblet cell, Safety, Biomarker, ONC, Poster, Standard of care, Regulation, NASDAQ, Roche, Oncology, Birth control, Pharmaceutical industry, Medical imaging, Oncolytics Biotech

(NASDAQ: ONCY) (TSX: ONC) today reported interim results from the phase 1/2 GOBLET study's first-line advanced/metastatic pancreatic ductal adenocarcinoma (PDAC) cohort in an abstract published as part of the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting.

Key Points: 
  • (NASDAQ: ONCY) (TSX: ONC) today reported interim results from the phase 1/2 GOBLET study's first-line advanced/metastatic pancreatic ductal adenocarcinoma (PDAC) cohort in an abstract published as part of the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting.
  • "Further, PD-(L)1 inhibitors only benefit fewer than one percent of pancreatic cancer patients classified as MSI-high.
  • Dr. Matt Coffey, President and Chief Executive Officer of Oncolytics Biotech Inc., commented, "GOBLET's interim results represent a crucial clinical milestone, providing robust proof-of-concept in a difficult-to-treat indication.
  • Alongside this potential PDAC opportunity, Oncolytics continues to advance pelareorep towards a registration study in metastatic breast cancer.

Oncolytics Biotech® Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 37th Annual Meeting

Retrieved on: 
Wednesday, October 5, 2022
Time, Pancreatic cancer, ONC, Neoplasm, TSX, SITC, NASDAQ, Patient, Biotechnology, Phenotype, Research, Annual general meeting, Cancer, Immunotherapy, Convention center, Stage 2, Boston Convention and Exhibition Center, Company, Society, Pelareorep, ORR, Securities Exchange Act of 1934, 2012 Vuelta a España, Stage 1 to Stage 11, Safety, 2021 Essex County Council election, KOL, Clinical trial, CEACAM6, Forward-looking statement, Lymphatic system, Travel, COVID-19, AB, Society for Immunotherapy of Cancer, Biomarker, Poster, Regulation, Pharmaceutical industry, Communications satellite, Interior design, Medical imaging, Oncolytics Biotech

SAN DIEGO, and CALGARY, AB, Oct. 5, 2022 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced the acceptance of two abstracts for poster presentations at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, which is taking place both virtually and in-person at the Boston Convention and Exhibition Center in Boston, MA, from November 8 – 12, 2022.

Key Points: 
  • (NASDAQ: ONCY) (TSX: ONC) today announced the acceptance of two abstracts for poster presentations at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, which is taking place both virtually and in-person at the Boston Convention and Exhibition Center in Boston, MA, from November 8 12, 2022.
  • Additional details on the abstracts and corresponding poster presentations are shown below.
  • Investors should consult Oncolytics' quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements.
  • The Company does not undertake any obligation to update these forward-looking statements, except as required by applicable laws.

Oncolytics Biotech® Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 37th Annual Meeting

Retrieved on: 
Wednesday, October 5, 2022
Time, Pancreatic cancer, ONC, Neoplasm, TSX, SITC, NASDAQ, Patient, Biotechnology, Phenotype, Research, Annual general meeting, Cancer, Immunotherapy, Convention center, Stage 2, Boston Convention and Exhibition Center, Company, Society, Pelareorep, ORR, Securities Exchange Act of 1934, 2012 Vuelta a España, Stage 1 to Stage 11, Safety, 2021 Essex County Council election, KOL, Clinical trial, CEACAM6, Forward-looking statement, Lymphatic system, Travel, COVID-19, AB, Society for Immunotherapy of Cancer, Biomarker, Poster, Regulation, Pharmaceutical industry, Communications satellite, Interior design, Medical imaging, Oncolytics Biotech

SAN DIEGO, and CALGARY, AB, Oct. 5, 2022 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced the acceptance of two abstracts for poster presentations at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, which is taking place both virtually and in-person at the Boston Convention and Exhibition Center in Boston, MA, from November 8 – 12, 2022.

Key Points: 
  • (NASDAQ: ONCY) (TSX: ONC) today announced the acceptance of two abstracts for poster presentations at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, which is taking place both virtually and in-person at the Boston Convention and Exhibition Center in Boston, MA, from November 8 12, 2022.
  • Additional details on the abstracts and corresponding poster presentations are shown below.
  • Investors should consult Oncolytics' quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements.
  • The Company does not undertake any obligation to update these forward-looking statements, except as required by applicable laws.

Oncolytics Biotech® Reports First Quarter 2022 Financial Results and Recent Operational Highlights

Retrieved on: 
Thursday, May 5, 2022
CAR, European Society for Medical Oncology, Breast cancer, Mouse, NASDAQ, Company, Neoplasm, Science Translational Medicine, TME, Roche, Safety, Tumor microenvironment, Pancreatic cancer, LINK, ESMO, PR, Patient, Brain, Paul Ehrlich Institute, Breast, Review, Recurrence, Data monitoring committee, Survival, International, Letrozole, Oncolytics Biotech, Paclitaxel, ONC, Risk, Cell, Skin, Prognosis, Classification, Oncology, Anal cancer, TSX, CEACAM6, PEI, Investor relations, DSMB, AB, Online gambling, Pharmaceutical industry, Medical imaging, Video game

(NASDAQ: ONCY) (TSX: ONC) today announced recent operational highlights and financial results for the first quarter ended March 31, 2022.

Key Points: 
  • (NASDAQ: ONCY) (TSX: ONC) today announced recent operational highlights and financial results for the first quarter ended March 31, 2022.
  • Operating expense for the first quarter of 2022 was $2.6 million, compared to $3.1 million for the first quarter of 2021.
  • R&D expense for the first quarter of 2022 was $3.7 million, compared to $2.8 million for the first quarter of 2021.
  • Net cash used in operating activities for the first quarter of 2022 was $6.3 million, compared to $5.6 million for the first quarter of 2021.

Oncolytics Biotech® Reports First Quarter 2022 Financial Results and Recent Operational Highlights

Retrieved on: 
Thursday, May 5, 2022
CAR, European Society for Medical Oncology, Breast cancer, Mouse, NASDAQ, Company, Neoplasm, Science Translational Medicine, TME, Roche, Safety, Tumor microenvironment, Pancreatic cancer, LINK, ESMO, PR, Patient, Brain, Paul Ehrlich Institute, Breast, Review, Recurrence, Data monitoring committee, Survival, International, Letrozole, Oncolytics Biotech, Paclitaxel, ONC, Risk, Cell, Skin, Prognosis, Classification, Oncology, Anal cancer, TSX, CEACAM6, PEI, Investor relations, DSMB, AB, Online gambling, Pharmaceutical industry, Medical imaging, Video game

(NASDAQ: ONCY) (TSX: ONC) today announced recent operational highlights and financial results for the first quarter ended March 31, 2022.

Key Points: 
  • (NASDAQ: ONCY) (TSX: ONC) today announced recent operational highlights and financial results for the first quarter ended March 31, 2022.
  • Operating expense for the first quarter of 2022 was $2.6 million, compared to $3.1 million for the first quarter of 2021.
  • R&D expense for the first quarter of 2022 was $3.7 million, compared to $2.8 million for the first quarter of 2021.
  • Net cash used in operating activities for the first quarter of 2022 was $6.3 million, compared to $5.6 million for the first quarter of 2021.

Oncolytics Biotech® Provides Positive Safety Update on the Third-Line Metastatic Colorectal Cancer Cohort of its Multi-Indication Phase 1/2 Gastrointestinal Cancer Trial

Retrieved on: 
Thursday, March 31, 2022
Colorectal cancer, Company, Cancer, Biomarker, Anal cancer, Data monitoring committee, Pancreatic cancer, NASDAQ, Forward-looking statement, Clinical trial, Stage 2, ORR, KRAS, PR, PEI, Research, DKG, Biotechnology, Neoplasm, Achievement, Lymphatic system, AIO, Key Stage 1, American Cancer Society, Prevalence, TSX, Roche, GI, Travel, Safety, Review, Securities Exchange Act of 1934, Paul Ehrlich Institute, Time, AB, COVID-19, Regulation, Science, DSMB, Phenotype, SAN, Patient, CEACAM6, ONC, Pharmaceutical industry, Medical imaging, Oncolytics Biotech

 SAN DIEGO, Calif. and CALGARY, AB, March 31, 2022 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced the successful completion of the three-patient safety run-in for the third-line metastatic colorectal cancer (mCRC) cohort of the phase 1/2 GOBLET study, following an independent review by the study's Data Safety Monitoring Board (DSMB). The DSMB noted no safety concerns in these patients and has recommended that the study proceed to full enrollment pending clearance by the Paul Ehrlich Institute (PEI; Germany's medical regulatory body). The PEI recently cleared the study's pancreatic cancer cohort for full enrollment following a similar recommendation by the DSMB. The trial's anal cancer and first-line mCRC cohorts do not include safety run-ins and are proceeding as planned.

Key Points: 
  • The PEI recently cleared the study's pancreatic cancer cohort for full enrollment following a similar recommendation by the DSMB.
  • The trial's anal cancer and first-line mCRC cohorts do not include safety run-ins and are proceeding as planned.
  • The GOBLET study is designed to evaluate the safety and efficacy of pelareorep in combination with Roche's anti-PD-L1 checkpoint inhibitor atezolizumab in patients with metastatic pancreatic, metastatic colorectal, and advanced anal cancers.
  • The study includes 14 clinical trial sites across Germany and is being managed by AIO, a leading academic cooperative medical oncology group.